Abdel-Hamid Z Abdel-Hamid (Hassan Z Ghanem, Abdel-Hamid Z Abdel Hamid)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Topics

Recombinant Human

Mesenchymal Stem Cells

Top Venues

Therapeutic delivery

Future science OA

This page only lists publications with an associated author ORCID identifier.

Publications

Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Alleviation of doxorubicin adverse effects via loading into various drug-delivery systems: a comparative study. Therapeutic delivery (2024)
Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Alleviation of doxorubicin adverse effects via loading into various drug-delivery systems: a comparative study. Therapeutic delivery 15 (6) (2024)
Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy: ABCA/P53/C-myc crosstalk. Future science OA 10 (1) (2024)
Mai O Kadry, Abdel-Hamid Z Abdel-Hamid, Rehab M Abdel-Megeed
Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study. Future science OA 10 (1) (2024)
Mai O Kadry, Abdel-Hamid Z Abdel-Hamid, Rehab M Abdel-Megeed
Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study. Future science OA 10 (1) (2024)
Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Alleviation of doxorubicin adverse effects via loading into various drug-delivery systems: a comparative study. Therapeutic delivery 15 (6) (2024)
Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Alleviation of doxorubicin adverse effects via loading into various drug-delivery systems: a comparative study. Therapeutic delivery 15 (6) (2024)
Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Alleviation of doxorubicin adverse effects via loading into various drug-delivery systems: a comparative study. Therapeutic delivery (2024)
Rehab M Abdel-Megeed, Abdel-Hamid Z Abdel-Hamid, Mai O Kadry
Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy: ABCA/P53/C-myc crosstalk. Future science OA 10 (1) (2024)